J&J submits MAA for telaprevir in HCV
This article was originally published in Scrip
Executive Summary
Hoping to take some of the focus away from manufacturing problems that it has faced in recent times, Johnson & Johnson has announced that its Janssen-Cilag International subsidiary has submitted a marketing authorization application to the European Medicines Agency (EMA) for telaprevir, an investigational, oral direct-acting anti-viral to treat chronic genotype 1 hepatitis C virus (HCV).